REMATIQ wants to Speed up the Approval of Medical Devices

Berlin-based startup REMATIQ has raised €5.4 million in seed funding to advance its AI platform that streamlines regulatory compliance for medical technology companies. According to information from the company's press release, the funding round was led by Project A Ventures, with participation from Amino Collective and HelloWorld, alongside notable angel investors including SaaS founder Boris Lokschin and industry expert Timo Fleßner.

REMATIQ's platform tackles one of the biggest hurdles in the MedTech industry – the overwhelming regulatory burden that currently consumes over 40% of R&D teams' time. Using artificial intelligence, the system analyzes complex regulatory documents and instantly delivers actionable requirements that integrate with existing development and quality processes.

The technology can reduce documentation efforts by up to 90%, effectively turning compliance from a bottleneck into a competitive advantage. This efficiency enables medical innovations – from wound care products to advanced CT scanners – to reach patients more quickly without compromising on safety.

"Regulatory requirements shouldn't slow down innovation – they should help accelerate it," said David Boutellier, Co-Founder and CEO of REMATIQ. The company plans to use the new funding to enhance its AI technology, grow its engineering team, and expand operations across Europe and the United States.

Founded in 2023 by Boutellier and Florian Scherer, REMATIQ has already partnered with leading MedTech companies worldwide, including B. Braun Group, whose Head of PLM Digitalization & Regulatory Intelligence praised the platform's AI-based approach to managing regulatory requirements.